128 related articles for article (PubMed ID: 9854426)
1. Immunoexpression of mutant p53 and human papillomavirus related E6 oncoprotein in anal malignancies.
Gupta S; Sharma BK
Indian J Exp Biol; 1998 Sep; 36(9):875-8. PubMed ID: 9854426
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of mutant P53 protein and human papillomavirus-related E6 protein in anal cancers.
Jakate SM; Saclarides TJ
Dis Colon Rectum; 1993 Nov; 36(11):1026-9. PubMed ID: 8223054
[TBL] [Abstract][Full Text] [Related]
4. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
5. The role of TP53 in Cervical carcinogenesis.
Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
[TBL] [Abstract][Full Text] [Related]
6. Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA.
Lu DW; El-Mofty SK; Wang HL
Mod Pathol; 2003 Jul; 16(7):692-9. PubMed ID: 12861066
[TBL] [Abstract][Full Text] [Related]
7. Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis.
Cheng YW; Wu TC; Chen CY; Chou MC; Ko JL; Lee H
Clin Cancer Res; 2008 Nov; 14(22):7173-9. PubMed ID: 19010833
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus infection and p53 nuclear overexpression in anal canal carcinoma.
Indinnimeo M; Cicchini C; Stazi A; Giarnieri E; French D; Limiti MR; Ghini C; Vecchione A
J Exp Clin Cancer Res; 1999 Mar; 18(1):47-52. PubMed ID: 10374676
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
10. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
[TBL] [Abstract][Full Text] [Related]
11. HPV-16 E6 oncoprotein induces mutations via p53-dependent and -independent pathways.
Kim HJ; Guo W; Park NH
Oncol Rep; 2000; 7(4):707-12. PubMed ID: 10854530
[TBL] [Abstract][Full Text] [Related]
12. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
Pim D; Banks L
Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
[TBL] [Abstract][Full Text] [Related]
13. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
14. [Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma].
Bian J; Yu X; Dong J; Zhao W; Zhou Y; Luan Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):271-3. PubMed ID: 15617346
[TBL] [Abstract][Full Text] [Related]
15. Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer.
Hsu NY; Cheng YW; Chan IP; Ho HC; Chen CY; Hsu CP; Lin MH; Chou MC
Oncol Rep; 2009 Jan; 21(1):81-7. PubMed ID: 19082446
[TBL] [Abstract][Full Text] [Related]
16. The role of the E6-p53 interaction in the molecular pathogenesis of HPV.
Thomas M; Pim D; Banks L
Oncogene; 1999 Dec; 18(53):7690-700. PubMed ID: 10618709
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6.
Crook T; Ludwig RL; Marston NJ; Willkomm D; Vousden KH
Virology; 1996 Mar; 217(1):285-92. PubMed ID: 8599213
[TBL] [Abstract][Full Text] [Related]
18. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
[TBL] [Abstract][Full Text] [Related]
19. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
20. p53-independent abrogation of a postmitotic checkpoint contributes to human papillomavirus E6-induced polyploidy.
Liu Y; Heilman SA; Illanes D; Sluder G; Chen JJ
Cancer Res; 2007 Mar; 67(6):2603-10. PubMed ID: 17363579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
